๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

On-Treatment HBsAg Level Can Early Predict Sustained Virological Response in Chronic Hepatitis B, HBeAg Negative Patients Treated With Peginterferon ALPHA-2A

โœ Scribed by Phisalprapa, Pochamana ;Charatcharoenwitthaya, Phunchai ;Chainuvati, Siwaporn P. ;Nimanong, Supot ;Pausawasdi, Nonthalee ;Prachayakul, Varayu ;Pongprasobchai, Supot ;Leelakusolvong, Somchai ;Manatsathit, Sataporn ;Kachintorn, Udom ;Tanwandee, Tawesak

Book ID
122175493
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
47 KB
Volume
140
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Early on-treatment prediction of respons
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
โœ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 189 KB ๐Ÿ‘ 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.